TransMedics(US:TMDX) Prnewswireยท2025-05-08 20:05Core Insights - TransMedics Group, Inc. reported strong financial performance for Q1 2025, with total revenue of $143.5 million, representing a 48% increase from $96.9 million in Q1 2024, driven by increased utilization of the Organ Care System (OCS) and logistics services [2][5] - The company raised its full-year 2025 revenue guidance to a range of $565 million to $585 million, indicating a 30% growth at the midpoint compared to the previous year's revenue [6] Financial Performance - Total revenue for Q1 2025 was $143.5 million, a 48% increase compared to $96.9 million in Q1 2024, primarily due to increased OCS utilization in liver and heart transplants [2] - Gross margin for Q1 2025 was 61%, slightly down from 62% in Q1 2024, but up from 59% in Q4 2024, attributed to a higher proportion of service revenue [3] - Operating expenses for Q1 2025 were $60.8 million, up from $47.5 million in Q1 2024, driven by increased research and development investments and organizational growth [4] - Net income for Q1 2025 was $25.7 million, or 18% of revenue, compared to $12.2 million in Q1 2024 [5] Strategic Developments - The company announced plans to open a design center of excellence and a new disposables manufacturing facility in Mirandola, Italy [7] - TransMedics hosted an annual symposium at the ISHLT 45th Annual Meeting, showcasing the clinical value of OCS and NOP through 10 abstracts and presentations [7] Operational Highlights - As of March 31, 2025, TransMedics owned 21 aircraft, supporting its logistics capabilities for organ transportation [7] - Cash reserves stood at $310.1 million as of March 31, 2025, reflecting a strong liquidity position [5]